Ultragenyx Stock Plummets After Phase 3 Trial Failure for Angelman Syndrome Treatment
Ultragenyx Pharmaceuticals (RARE) experienced a significant stock decline of nearly 47% after its experimental treatment, apazunersen, failed in final-phase clinical trials. The drug was being tested as a potential therapy for Angelman syndrome, which causes developmental delays and speech impairments. In the Phase 3 trial, patients treated with Ultragenyx's drug did not show improvements in cognition or meet secondary endpoints such as composite scores assessing patient response. This outcome has raised concerns about the company’s pipeline and its ability to deliver effective treatments for rare diseases.
Tickers: $RARE
Topics: Biotech Pharmaceuticals Stock Movement